ReviewToxicon: X2026
Venom variation and the future of antivenom design: Integrating population venomics, evolutionary toxinology, and precision therapeutics.
Review in Toxicon: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- BrazilianToxins · 2026Article
- Exploiting the Property of a New Series of 1,2,3-Triazole Compounds as Inhibitors of In Vivo and In Vitro Toxic Effects Caused byTropical medicine and infectious disease · 2026Article
- Geographic heterogeneity of Deinagkistrodon acutus venom: A multi-regional study of toxicity, proteomics, and antivenom efficacy.PLoS neglected tropical diseases · 2026Article
- Dissecting conserved molecular mechanisms of biological toxin activity through CRISPR screening.Biochemical Society transactions · 2026Review
- Preliminary Insights into Geographic Variation in Venom Profiles and Functional Activities of Nigerian Snakes,Toxins · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Snakebite envenoming remains a neglected tropical disease that disproportionately affects rural populations in the tropical regions, where access to timely and effective treatment is often limited. Conventional antivenoms, produced by immunizing animals with pooled venoms, have demonstrated clinical benefit but may show variable performance against the complex and geographically heterogeneous composition of snake venoms. Advances in proteomics, transcriptomics, and genomics have revealed substantial intra- and interspecies variation in venom composition with potential implications for antivenom design and evaluation. This review synthesizes current knowledge on the molecular, ecological, and evolutionary drivers of venom diversity and discusses how these insights may inform the development of more regionally informed and evidence-based therapeutic strategies. Particular attention is given to toxin-resolved antivenomics, monoclonal antibody-based approaches, recombinant platforms, and emerging computational tools for antigen prioritization. The potential role of rapid diagnostics and immunoinformatics in supporting clinical decision-making is also considered. Overall, the review highlights how population-level venom data and translational research may contribute to evidence-based improvements in antivenom design, while acknowledging the regulatory, economic, and implementation challenges involved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.